Most publicly traded weed companies saw their share prices wilt this week. Among the more significant decliners were Charlotte's Web Holdings (CWBHF 2.65%) and Organigram (OGI 3.00%), both of which fell by around 20% across the five-day stretch. Up-and-comers Flora Growth (FLGC -11.54%) and IM Cannabis (IMCC -5.18%) took even harder hits, with both declining at a roughly 26% clip.
There weren't any all-encompassing and powerful negative developments in marijuana; rather, last week seemed to be more of a "no news is bad news" situation in the world's potentially most important weed market.
Earlier this year, it seemed that great progress was being made on the U.S. legalization/decriminalization front. Several states flipped the switch on either medical or recreational cannabis, and a new decriminalization bill was introduced in the Senate.
But almost no legislative progress has been made since then, and the clock is ticking for the cannabis sector. Many weed companies are continuing to burn cash. Time isn't on their side, and they could really use the boost that greater cannabis law liberalization will bring.
Other factors are affecting this particular set of stocks. At the end of last week, Charlotte's Web was hit by a recommendation downgrade from Piper Sandler, from overweight (read:buy) to neutral. Flora Growth, meanwhile, posted half-year results which showed encouraging growth yet revealed the company was well in the red on the bottom line.
All in all, though, this week appeared to prove that the cannabis industry's fortunes are still firmly tied to marijuana legalization...or the lack thereof.